心力衰竭治疗进展述评  

The therapeutic advancement in heart failure

作　　者：杨永健[1] 

机构地区：[1]成都军区总医院,四川成都610083

出　　处：《西部医学》2016年第3期297-299,303,共4页Medical Journal of West China

基　　金：国家自然科学基金(81070191;81500208;81470396)

摘　　要：随着人们对心衰发病机理的不懈探知,心力衰竭(心衰)治疗方法不断取得新的进展。目前心脏再同步化治疗、醛固酮受体拮抗剂、血管紧张素Ⅱ受体与脑啡肽酶的双重抑制剂、超极化激活的环核苷酸门控通道抑制剂和补铁制剂等被证实有利于射血分数减少型心衰(HFrEF)的治疗。但是有关急性心衰和射血分数保留型心力衰竭(HFpEF)的治疗研究尚未取得突破,迫切需要进一步深入研究。为此,本文就心力衰竭治疗进展做一述评,供基础与临床研究借鉴。With great efforts to explore the pathogenesis of heart failure,many new breakthroughs have been gradually achieved in the treatment.Up to date,there have been some measurements exhibiting therapeutic effects in heart failure with reduced ejection fraction,such as cardiac resynchronization therapy,aldosterone receptor antagonist,dual-acting inhibitors of angiotensin II receptor and neprilysin,inhibitors of hyperpolarization-activated cyclic nucleotidegated channel,and ferric carboxymaltose.However,there are still no good ways to treat acute heart failure and heart failure with preserved ejection fraction.

关 键 词：心力衰竭 心脏再同步化治疗 药物治疗 基因治疗 

分 类 号：R541.6[医药卫生—心血管疾病]